Patents Assigned to Transcend Therapeutics, Inc.
  • Patent number: 11969407
    Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: April 30, 2024
    Assignee: TRANSCEND THERAPEUTICS, INC.
    Inventors: Blake Mandell, Martin Stogniew, Jennifer Louise Schmidt, Markus Seelig
  • Publication number: 20240058301
    Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
    Type: Application
    Filed: November 2, 2023
    Publication date: February 22, 2024
    Applicant: Transcend Therapeutics, Inc.
    Inventors: Blake MANDELL, Martin STOGNIEW, Jennifer Louise SCHMIDT, Markus SEELIG
  • Publication number: 20230338333
    Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Applicant: Transcend Therapeutics, Inc.
    Inventors: Blake MANDELL, Martin Stogniew, Jennifer Louise Schmidt, Markus Seelig
  • Patent number: 11707446
    Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: July 25, 2023
    Assignee: TRANSCEND THERAPEUTICS, INC.
    Inventors: Blake Mandell, Martin Stogniew, Jennifer Louise Schmidt, Markus Seelig
  • Publication number: 20230054211
    Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.
    Type: Application
    Filed: August 15, 2022
    Publication date: February 23, 2023
    Applicant: Transcend Therapeutics, Inc.
    Inventors: Blake MANDELL, Martin STOGNIEW, Jennifer Louise SCHMIDT, Markus SEELIG
  • Patent number: 5869679
    Abstract: Method for synthesizing L-2-oxothiazolidine-4-carboxylate and its acid, L-2-oxothiazolidine-4-carboxylic acid. The present invention involves the separation of phenol from a reaction mixture containing L-2-oxothiazolidine-4-carboxylate and phenol. In the present method a reaction mixture containing phenol, L-2-oxothiazolidine-4-carboxylate, and chloride salt, is contacted with a phenol adsorbing adsorption resin, the adsorption resin comprising a polymer having a polyethylene backbone. The adsorption resin is capable of adsorbing substantially all of the phenol while not adsorbing substantial amounts of the L-2-oxothiazolidine-4-carboxylate from the reaction mixture.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: February 9, 1999
    Assignee: Transcend Therapeutics, Inc.
    Inventors: Francis H. Verhoff, L. Reade Baxley, Xiaofeng Lin, Gordon J. Rossiter
  • Patent number: 5824693
    Abstract: The present invention provides a method for treating pulmonary disease. More specifically, the present invention provides a method for treating diseases such as adult respiratory distress syndrome which result in oxidative stress that damages the cells of the lung. Pursuant to present invention, a method is provided that increases the intracellular glutathione levels of at least the cells of the lungs of a patient with pulmonary disease. To this end, a non-cysteine substrate that is a precursor for the intracellular synthesis of glutathione is administered to the patient.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 20, 1998
    Assignee: Transcend Therapeutics, Inc.
    Inventor: Dennis I. Goldberg